- Sangamo Therapeutic, Inc. (NASDAQ: SGMO) is a clinical-stage biotech focused on genomic medicines using proprietary platform technologies covering gene therapy, ex-vivo gene-edited cell therapy, and in-vivo genome editing/regulation.
- Sangamo is positioned with a pipeline covering 18 potential therapeutics across targets ranging from Hemophilia A to Alzheimer's across pre-clinical to Phase 3.
- Sangamo entered into a new three-year agreement worth $795M with Novartis for the research, development, and commercialization of gene-therapies for treating three neurodevelopmental disorders.
- Sangamo's financial position is excellent with $665M in cash (1H 2020) and a 3-year CAGR of 41% reaching revenues of $102M in 2019.
- In summary, with two-new partnerships, a massive pipeline of 18 therapeutics, and cash sufficient to cover clinical costs, SGMO is a "buy" at a 1-year price target of $12.22 (+29% upside).
For further details see:
Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 Therapeutics And 2 New 2020 Partnerships, 29% Upside